---
title: "Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. (688621.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688621.SH.md"
symbol: "688621.SH"
name: "Beijing Sun-Novo Pharmaceutical Research Co.,Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T05:30:15.460Z"
locales:
  - [en](https://longbridge.com/en/quote/688621.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688621.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688621.SH.md)
---

# Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. (688621.SH)

## Company Overview

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products. In addition, the company operates quantitative pharmacology platform that use technology on pharmacokinetics, pharmacodynamics, body function, disease mechanism and test process, and other information for quantitative research; and mass spectrometry, immunological analysis, cell biology, and molecular biology platforms that provide biological analysis services for large and small molecular drugs, as well as operates as a Contract Research Organization for Professional Peptide Drug Research and Development.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.sun-novo.com](https://www.sun-novo.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.38)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 7 / 25 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 12.44% |  |
| Net Profit YoY | 45.21% |  |
| P/B Ratio | 5.07 |  |
| Dividend Ratio | 0.28% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6368427444.40 |  |
| Revenue | 1190618100.80 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 17.07% | A |
| Profit Margin | 16.40% | A |
| Gross Margin | 49.34% | B |
| Revenue YoY | 12.44% | B |
| Net Profit YoY | 45.21% | B |
| Total Assets YoY | 7.72% | B |
| Net Assets YoY | 23.08% | A |
| Cash Flow Margin | 4.19% | D |
| OCF YoY | 12.44% | B |
| Turnover | 0.54 | C |
| Gearing Ratio | 44.89% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "12.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "45.21%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.07",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.28%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6368427444.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1190618100.80",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "17.07%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "16.40%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "49.34%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "12.44%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "45.21%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.72%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "23.08%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "4.19%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "12.44%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.89%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 32.61 | 3/25 | 56.33 | 52.15 | 42.74 |
| PB | 5.07 | 24/25 | 6.90 | 6.20 | 5.63 |
| PS (TTM) | 5.35 | 9/25 | 7.52 | 6.84 | 5.72 |
| Dividend Yield | 0.28% | 12/25 | 0.29% | 0.25% | 0.23% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-03T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 56.78 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688621.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688621.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688621.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**